Related Experiment Video
Updated: May 2, 2026

DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
A preliminary step of a novel strategy in suicide gene therapy with lentiviral vector
Jahan Afrooz Ghanbari1, Mansoor Salehi1, Arezoo Karam Zadeh1
1Department of Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran.
Background:
One of the challenges in lentiviral vector-based suicide gene therapy by toxin or apoptosis-inducing genes is death of packaging cells. Therefore, the process of production of these lentiviral particles would be stopped in this step. We proposed that insertion of a reverse promoter between R and U5 regions of 5' long terminal repeat (LTR) in transfer plasmid could be considered as a solution for this problem. But it is not known, whether the insertion of RΔU3 sequence between the promoter and target gene in proviral genome during the life-cycle of lentivirus may interfere whit gene expression in target cells.
Materials And Methods:
THE FOLLOWING WERE PERFORMED IN THIS STUDY: insertion of RΔU3 sequence in pEGFP-N1 plasmid, evaluation of the expression of eGFP gene after calcium phosphate co-precipitation transfection of pCMV-RΔU3-GFP construction in 293T cells, and quantitative assay of eGFP gene by flow cytometry technique.
Results:
Our results from flow cytometry technique analysis showed that there was no significant difference between the expression of eGFP gene in transfected cells with pEGFP-N1 and pCMV-RΔU3-GFP plasmids (P > 0.05).
Conclusion:
In this step of our strategy, we demonstrated that modification of orientation and location of promoter may overcome some issues in lentiviral suicide gene therapy, especially when toxin or apoptosis-inducing genes are used.
More Related Videos
06:33Author Spotlight: Exploring Macrophage Immunometabolism Through Lentiviral Vector-Mediated Gene Manipulation
Published on: February 16, 2024
13:47Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
Published on: March 29, 2019